Aspirin Plus Clopidogrel After Minor Stroke: Reading POINT and CHANCE

The short answer is that the 21-day window for aspirin plus clopidogrel after a minor stroke or high-risk transient ischemic attack (TIA) did not come from one clean experiment. It emerged when investigators pooled patient-level data from two large trials, CHANCE and POINT, and looked at the timing of events. The combination prevented early recurrent strokes, but that protection was front-loaded into the first weeks, while the extra bleeding risk kept climbing the longer patients stayed on both drugs. Twenty-one days is roughly where those two curves separate most favorably. This article is educational and is not medical advice.

Two trials asking a similar question

CHANCE, published in 2013, enrolled 5,170 patients in China who had a minor ischemic stroke (a National Institutes of Health Stroke Scale, or NIHSS, score of 3 or lower) or a high-risk TIA (an ABCD2 score of 4 or higher), all within 24 hours of symptom onset. Patients received either aspirin alone or aspirin plus clopidogrel, with the clopidogrel continued for 90 days and the aspirin overlapping for the first 21 days. Recurrent stroke at 90 days fell from 11.7 percent to 8.2 percent, a hazard ratio of about 0.68, and serious bleeding was rare and similar between groups.

POINT, published in 2018, asked nearly the same question in a mostly North American and European population of 4,881 patients, using the same NIHSS and ABCD2 eligibility. The key design difference: POINT kept both drugs running for the full 90 days. The composite of ischemic stroke, myocardial infarction, or vascular death dropped from 6.5 percent to 5.0 percent, and recurrent ischemic stroke fell in step. But major hemorrhage roughly doubled, occurring in 0.9 percent of the dual-therapy group versus 0.4 percent on aspirin alone. The trial was stopped early once that bleeding signal became clear.

So two well-run trials agreed on the headline: adding clopidogrel early prevents strokes. They disagreed, by design, on how long to keep going, and POINT surfaced the bleeding cost that CHANCE's shorter aspirin overlap had largely avoided.

What the pooled analysis actually showed

The decisive evidence came from a pooled, patient-level analysis of CHANCE and POINT published in JAMA Neurology in 2019, covering just over 10,000 patients. Instead of comparing 90-day totals, the authors split follow-up into two intervals and asked when events happened.

In days 0 through 21, dual therapy reduced major ischemic events from 7.8 percent to 5.2 percent, an adjusted hazard ratio of 0.66 (95 percent confidence interval 0.56 to 0.77). That is a substantial, statistically robust reduction. In days 22 through 90, the story changed. The hazard ratio was 0.94 (confidence interval 0.67 to 1.32), which is to say no meaningful difference at all. Most of the ischemic benefit landed in those first three weeks.

Meanwhile, major hemorrhage moved in the opposite direction over time. Bleeding events showed a nonsignificant upward trend during the first 21 days and continued to accumulate afterward, so that keeping patients on two agents past three weeks added hemorrhage risk without adding stroke protection. The authors' conclusion was direct: the benefit of dual antiplatelet therapy appeared confined to the first 21 days.

Why the recommendation landed on 21 days

Put the two dynamics side by side. The risk of a recurrent stroke is highest in the immediate aftermath of the first event and decays quickly, which is why an aggressive early strategy pays off and why every trial insisted on starting within 24 hours. Bleeding risk, by contrast, is roughly a function of cumulative exposure; each additional day on two antiplatelet drugs adds a little more hazard.

Early on, the large stroke-prevention benefit dwarfs the small bleeding cost. As the recurrence risk fades, the ledger shifts. By roughly three weeks, the incremental stroke protection has largely been banked, but the bleeding meter keeps running. Twenty-one days is a defensible stopping point precisely because it captures nearly all of the benefit while limiting the exposure that drives harm. What the number represents matters here: it is a population-level optimization of a benefit-risk trade-off over time, not a biological threshold at which platelets change behavior.

This is also why CHANCE and POINT, despite reaching similar efficacy conclusions, left different impressions about safety. CHANCE overlapped the two drugs for only 21 days and saw little excess bleeding; POINT ran the overlap to 90 days and saw the bleeding signal that a longer exposure predicts. The pooled timing analysis reconciled them.

How this reads in practice

Major guideline bodies converged on short-course dual antiplatelet therapy, generally initiated within 24 hours and continued for about 21 days, for patients with a genuinely minor stroke or a high-risk TIA who do not have a competing indication such as atrial fibrillation requiring anticoagulation. The eligibility thresholds matter: these trials studied low NIHSS scores and higher-risk TIAs, so the evidence does not automatically extend to larger strokes, where hemorrhagic transformation is a greater concern.

Several open questions remain. Genetic variation in CYP2C19, the enzyme that activates clopidogrel, affects how well the drug works, and the CHANCE-2 trial explored ticagrelor as an alternative in loss-of-function carriers. Later work has also tested starting dual therapy in slightly wider time windows. Those refinements sit on top of the core lesson from CHANCE and POINT rather than replacing it: match the intensity and duration of treatment to when the risk actually is, and stop before the cost outweighs the gain.